Article Text


Improved survival with postoperative uracil-tegafur in stage 1 adenocarcinoma of the lung
  1. M H Lawson
  1. Senior House Officer, St Bartholomew’s Hospital, London, UK;

Statistics from

Tegafur is a pro-drug that is converted to fluorouracil, and the serum concentration of fluorouracil is enhanced by uracil. While fluorouracil itself has no apparent effect on survival in non-small cell lung cancer, Japanese studies of uracil-tegafur have reported a mortality benefit when used as an adjuvant therapy. In subgroup analysis this benefit was confined to adenocarcinoma.

The present study randomised patients to receive oral uracil-tegafur (250 mg/m2/day, n = 491) or no treatment (n = 488) for 2 years following resection of stage 1 (T1M0N0 or T2M0N0) adenocarcinoma of the lung. Despite being an open label study, it was well planned and adequately powered. Median follow up was 73 months. Overall there was a statistically significant survival advantage favouring treatment (p = 0.04) with a 5 year survival of 88% (CI 85 to 91) compared with 85% (CI 82 to 89). On subgroup analysis this difference was only apparent in those patients with T2 disease: 5 year survival with treatment was 85% (CI 79 to 91) compared with 74% without (CI 66 to 81). There were few serious drug related adverse events but only 61% of patients completed the 2 year treatment period.

This study shows a survival advantage for postoperative adjuvant oral uracil-tegafur in stage 1 (T2) adenocarcinoma of the lung.

View Abstract

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.